HUTCHMED is a biopharmaceutical company focused on discovering, developing and commercializing therapies for cancer and immunological diseases, with a strong base in China and international partnerships. Its portfolio spans targeted small molecules and other oncology assets, several of which have reached regulatory approval and commercial launch in major markets. The company combines in-house R&D with collaborations to bring innovative medicines to patients in China and beyond.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 426.4 | — | -360.8 | — |
| 2023 | 838 | 96.5% | 100.8 | — |
| 2024 | 630.2 | -24.8% | 37.7 | -62.6% |
| 2025 | 548.5 | -13% | 456.9 | 1,111% |
All markets — KeepWinning global stock screener
Other companies on London Stock Exchange: Oxford Instruments plc (OXIG), Genus plc (GNS), Clarkson PLC (CKN), Currys plc (CURY), Coats Group plc (COA), Sirius Real Estate Limited (SRE)